Original language | English |
---|---|
Number of pages | 1 |
Journal | Annals of Oncology |
Volume | 30 |
DOIs | |
Publication status | Published - Oct 2019 |
Externally published | Yes |
Event | 44th Congress of the European-Society-for-Medical-Oncology (ESMO) - Barcelona, Spain Duration: 27 Sept 2019 → 1 Oct 2019 |
Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
M. Voskoboynik, L. Mileshkin, H. Gan, M. Millward, G. Au-Yeung, T. M. Meniawy, G. Kichenadasse, K. Zhang, M. Zhang, S. Mu, J. D. Lickliter
Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review
5
Citations
(Web of Science)